GlassScriptPhysician profile
Martin R Zapata
NPI 1689628240
$6,775.97
in general payments reported to CMS, 2019-2025
39 companies · $2,331 in 2025
The $2,331 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $466 · 2021: $498 · 2022: $1,159 · 2023: $967 · 2024: $864 · 2025: $2,331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,142 · Education: $15.99 · Travel and Lodging: $4.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,142.05 |
| Education | $15.99 |
| Travel and Lodging | $4.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,191.77 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $1,067.57 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $549.16 | 2022-2025 | |
| Lilly USA, LLC | $419.21 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $373.40 | 2022-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $308.82 | 2023-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Amarin Pharma, INC. | $260.53 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $252.50 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.89 | 2022-2025 | Jardiance |
| Amgen INC. | $198.35 | 2023-2025 | Otezla, Repatha, Krystexxa |
| Horizon Therapeutics Plc | $192.93 | 2022-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $174.92 | 2023-2025 | Rexulti, Jynarque |
| Exact Sciences Corporation | $167.83 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $159.21 | 2024-2025 | Voquezna |
| Scilex Pharmaceuticals INC. | $103.04 | 2020-2025 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Zapata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.